Genzyme Providing Renagel At Discount To Seniors Ahead Of Medicare Rx
This article was originally published in The Pink Sheet Daily
Executive Summary
The REACH program will allow Medicare beneficiaries to receive the renal disease therapy by using a Medicare drug discount card. Genzyme expects Renagel scripts to grow at a "slightly higher pace;" REACH copays will go towards pharmacy costs.
You may also be interested in...
Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says
Renagel remains healthy despite competition from Shire's phosphate-control agent, the company maintains. Genzyme continues to see opportunities for its end-stage renal disease therapy with Medicare Part D.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability